AstraZeneca: Inavir, in collaboration with Incivo, has been approved in China for the first-line treatment of advanced or unresectable hepatocellular carcinoma in adult patients.

On April 27th, AstraZeneca announced that the National Medical Products Administration of China has officially approved the combination of Imfinzi with Iressa for first-line treatment in adult patients with advanced or unresectable hepatocellular carcinoma. In addition, durvalumab has also been approved for monotherapy as first-line treatment in adult patients with advanced or unresectable hepatocellular carcinoma.